Polypropylene small-diameter vascular grafts.
Polypropylene's physical properties (e.g., high tensile strength) and relatively inert behavior suggest that fabrication into an arterial substitute may result in an efficacious prosthesis. Grafts were woven from polypropylene yarn into conduits 4 mm I.D. x 50 mm in length. Control grafts were Dacron and ePTFE. Baseline platelet aggregometry on all dogs was performed with 10(-5) M ADP. Aspirin and dipyridamole were given for three days preoperatively and maintained for 2 weeks after surgery. Fifty-four grafts were placed into the aortoiliac position, two different graft materials per dog. The grafts were explanted at intervals of 2 weeks through 16 months; photographed for thrombus-free surface area determinations; and preserved for light, scanning, and transmission electron microscopy. Late (4-16 month) patency was 81% (13/16) for polypropylene, 69% (9/13) for Dacron, and 20% (1/5) for ePTFE. These data include one year patencies of 11/12 (92%) for polypropylene and 7/10 (70%) for Dacron. Late patency for polypropylene grafts was better than for PTFE (p less than 0.05). Platelet aggregation status did not predict graft patency. Light microscopy of 2-week polypropylene explants showed inner capsules composed of myofibroblasts and macrophages, with patchy areas of endothelial cells lining the lumen. By 1 month, a confluent endothelialized surface was seen in all polypropylene explants. Progressive thickening of inner capsules with myofibroblasts and collagen continued through 4 months, reaching a mean thickness of 142 +/- 50 microns (compared to 150 +/- 30 microns for Dacron). These findings suggest potential clinical efficacy for polypropylene as an arterial substitute.
Greisler
H P
HP
Loyola University Medical Center, Maywood, Illinois 60153.
Tattersall
C W
CW
Henderson
S C
SC
Cabusao
E A
EA
Garfield
J D
JD
Kim
D U
DU
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D001807:Blood Vessel Prosthesis; D004176:Dipyridamole / Q000627:therapeutic use; D004285:Dogs; D005549:Foreign-Body Reaction; D008854:Microscopy, Electron; D008855:Microscopy, Electron, Scanning; D010974:Platelet Aggregation / Q000187:drug effects; D011093:Polyethylene Terephthalates; D011126:Polypropylenes; D011138:Polytetrafluoroethylene; D014654:Vascular Patency
D011093:Polyethylene Terephthalates; D011126:Polypropylenes; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D011138:Polytetrafluoroethylene; D001241:Aspirin